Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Freeline Therapeutics Holdings Plc Adss (FRLN)
Freeline Therapeutics Holdings Plc Adss (FRLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,147
  • Shares Outstanding, K 4,341
  • Annual Sales, $ 0 K
  • Annual Income, $ -88,970 K
  • 60-Month Beta 0.68
  • Price/Sales 27.76
  • Price/Cash Flow N/A
  • Price/Book 0.39
Trade FRLN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -1.43
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -3.89
  • Prior Year -2.99
  • Growth Rate Est. (year over year) +52.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.11 +26.42%
on 09/05/23
4.45 -11.69%
on 09/20/23
-0.11 (-2.60%)
since 08/25/23
3-Month
2.30 +70.87%
on 06/30/23
8.70 -54.83%
on 07/12/23
+1.49 (+61.06%)
since 06/26/23
52-Week
2.11 +86.25%
on 05/25/23
12.00 -67.25%
on 10/06/22
-7.32 (-65.06%)
since 09/26/22

Most Recent Stories

More News
4 Stocks to AVOID Right Now

It could be potentially stormy this earnings season, given a tense economic backdrop due to the high inflation, rate hikes, and the banking crisis. So, it could be wise to avoid fundamentally weak stocks...

DLO : 18.81 (-0.90%)
FRLN : 3.83 (-3.04%)
KIRK : 1.6600 (-0.60%)
KRUS : 66.99 (-2.96%)
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

AXLA : 8.20 (-6.82%)
PLRX : 16.50 (+13.17%)
FRLN : 3.83 (-3.04%)
ABSI : 1.2950 (-4.07%)
DICE : 47.55 (+0.06%)
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted...

FRLN : 3.83 (-3.04%)
Here's Why Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could be Great Choice for a Bottom Fisher

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart...

FRLN : 3.83 (-3.04%)
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Upgraded to Buy: Here's What You Should Know

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher...

FRLN : 3.83 (-3.04%)
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON,...

FRLN : 3.83 (-3.04%)
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a...

FRLN : 3.83 (-3.04%)
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and...

FRLN : 3.83 (-3.04%)
10 Penny Stocks with > 1,000% Upside

Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...

AMTI : 0.1731 (-8.36%)
ANGN : 10.0000 (+2.04%)
CKPT : 1.4200 (-2.07%)
EFTR : 0.5100 (-0.97%)
FRLN : 3.83 (-3.04%)
GLYC : 1.4400 (+11.63%)
MGNX : 4.80 (+4.35%)
OCUP : 4.18 (+7.18%)
PHAS : 0.0701 (-26.21%)
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same...

FRLN : 3.83 (-3.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Freeline Therapeutics Holdings plc is a clinical-stage biotechnology company. It is focused on AAV-based gene therapy targeting the liver. The company operates principally in Germany and the U.S. Freeline Therapeutics Holdings plc is headquartered in the U.K.

See More

Key Turning Points

3rd Resistance Point 4.46
2nd Resistance Point 4.23
1st Resistance Point 4.09
Last Price 3.83
1st Support Level 3.72
2nd Support Level 3.49
3rd Support Level 3.35

See More

52-Week High 12.00
Fibonacci 61.8% 8.22
Fibonacci 50% 7.05
Fibonacci 38.2% 5.89
Last Price 3.83
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar